Havrilesky LJ - Search Results

1

Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.

Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, Alvarez Secord A, Yang JC, Johnson FR, Gonzalez JM, Reed SD. Havrilesky LJ, et al. Gynecol Oncol. 2020 Mar;156(3):561-567. doi: 10.1016/j.ygyno.2020.01.026. Epub 2020 Jan 22. Gynecol Oncol. 2020. PMID: 31982178

2

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Havrilesky LJ, et al. Gynecol Oncol. 2001 Dec;83(3):491-500. doi: 10.1006/gyno.2001.6464. Gynecol Oncol. 2001. PMID: 11733961

3

Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.

Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME. Havrilesky LJ, et al. Gynecol Oncol. 2003 Jan;88(1):51-7. doi: 10.1006/gyno.2002.6859. Gynecol Oncol. 2003. PMID: 12504627 Clinical Trial.

4

The role of PET scanning in the detection of recurrent cervical cancer.

Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. Havrilesky LJ, et al. Gynecol Oncol. 2003 Jul;90(1):186-90. doi: 10.1016/s0090-8258(03)00256-7. Gynecol Oncol. 2003. PMID: 12821362

5

A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.

Jones EL, Samulski TV, Dewhirst MW, Alvarez-Secord A, Berchuck A, Clarke-Pearson D, Havrilesky LJ, Soper J, Prosnitz LR. Jones EL, et al. Among authors: havrilesky lj. Cancer. 2003 Jul 15;98(2):277-82. doi: 10.1002/cncr.11475. Cancer. 2003. PMID: 12872345 Free article. Clinical Trial.

6

High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease.

Roth TM, Secord AA, Havrilesky LJ, Jones E, Clarke-Pearson DL. Roth TM, et al. Among authors: havrilesky lj. Gynecol Oncol. 2003 Oct;91(1):258-60. doi: 10.1016/s0090-8258(03)00443-8. Gynecol Oncol. 2003. PMID: 14529691

7

Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.

Havrilesky LJ, Leath CA, Huh W, Calingaert B, Bentley RC, Soper JT, Alvarez Secord A. Havrilesky LJ, et al. Gynecol Oncol. 2004 May;93(2):429-34. doi: 10.1016/j.ygyno.2004.01.038. Gynecol Oncol. 2004. PMID: 15099957

8

FDG-PET for management of cervical and ovarian cancer.

Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. Havrilesky LJ, et al. Gynecol Oncol. 2005 Apr;97(1):183-91. doi: 10.1016/j.ygyno.2004.12.007. Gynecol Oncol. 2005. PMID: 15790456

9

Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.

Alvarez Secord A, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW. Alvarez Secord A, et al. Among authors: havrilesky lj. Int J Hyperthermia. 2005 Jun;21(4):333-47. doi: 10.1080/02656730500110155. Int J Hyperthermia. 2005. PMID: 16019859 Free article. Clinical Trial.

10

Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.

Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Havrilesky LJ, et al. Gynecol Oncol. 2005 Dec;99(3):689-95. doi: 10.1016/j.ygyno.2005.07.014. Epub 2005 Aug 29. Gynecol Oncol. 2005. PMID: 16126261

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

262 results

Search Page